Skip to main navigation
Skip to search
Skip to main content
Korea University Pure Home
Search content at Korea University Pure
Home
Profiles
Research units
Equipment
Research output
Press/Media
Alirocumab and cardiovascular outcomes after acute coronary syndrome
ODYSSEY OUTCOMES Committees and Investigators
Research output
:
Contribution to journal
›
Article
›
peer-review
3006
Link opens in a new tab
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alirocumab and cardiovascular outcomes after acute coronary syndrome'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Coronary Syndrome
100%
Cardiovascular Outcomes
100%
Alirocumab
100%
Placebo Groups
33%
Low-density Lipoprotein Cholesterol Level
33%
Confidence Interval
22%
Placebo
22%
Statin Therapy
22%
Hazard Ratio
22%
Cardiovascular Events
22%
Adverse Events
11%
Monoclonal Antibody
11%
Coronary Artery Disease
11%
High Risk
11%
Cholesterol Levels
11%
Apolipoprotein B (Apo B)
11%
High-density Lipoprotein Cholesterol (HDL-C)
11%
Hospitalization
11%
Stable Angina
11%
Ischemic Stroke
11%
Non-fatal
11%
Randomized Placebo-controlled Trial
11%
Maximum Tolerated Dose
11%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
11%
Nonfatal Myocardial Infarction
11%
High-intensity Statin Therapy
11%
Local Injection Site Reaction
11%
Absolute Benefit
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Alirocumab
100%
Placebo
66%
Low Density Lipoprotein Cholesterol
33%
Statin (Protein)
33%
Adverse Event
11%
Heart Infarction
11%
Lipoprotein
11%
Unstable Angina Pectoris
11%
Ischemic Heart Disease
11%
Maximum Tolerated Dose
11%
Brain Ischemia
11%
Apolipoprotein B
11%
Injection Site Reaction
11%
Proprotein Convertase 9
11%
Human Monoclonal Antibody
11%